18-07-2025
- Business
- AU Financial Review
Mesoblast shares soar 35pc on strong cell therapy sales data
Biotech Mesoblast has reported strong initial sales of its cell therapy, Ryoncil, its first commercial product since the company was founded two decades ago, sending its shares soaring.
The US Food and Drug Administration approved the therapy to treat children for complications that can occur during bone marrow transplants last December, paving the way for the first commercial sales in March.
